Treatment-resistant depression: therapeutic trends, challenges, and future directions

Khalid Saad Al-Harbi, Khalid Saad Al-Harbi

Abstract

Background: Patients with major depression respond to antidepressant treatment, but 10%-30% of them do not improve or show a partial response coupled with functional impairment, poor quality of life, suicide ideation and attempts, self-injurious behavior, and a high relapse rate. The aim of this paper is to review the therapeutic options for treating resistant major depressive disorder, as well as evaluating further therapeutic options.

Methods: In addition to Google Scholar and Quertle searches, a PubMed search using key words was conducted, and relevant articles published in English peer-reviewed journals (1990-2011) were retrieved. Only those papers that directly addressed treatment options for treatment-resistant depression were retained for extensive review.

Results: Treatment-resistant depression, a complex clinical problem caused by multiple risk factors, is targeted by integrated therapeutic strategies, which include optimization of medications, a combination of antidepressants, switching of antidepressants, and augmentation with non-antidepressants, psychosocial and cultural therapies, and somatic therapies including electroconvulsive therapy, repetitive transcranial magnetic stimulation, magnetic seizure therapy, deep brain stimulation, transcranial direct current stimulation, and vagus nerve stimulation. As a corollary, more than a third of patients with treatment-resistant depression tend to achieve remission and the rest continue to suffer from residual symptoms. The latter group of patients needs further study to identify the most effective therapeutic modalities. Newer biomarker-based antidepressants and other drugs, together with non-drug strategies, are on the horizon to address further the multiple complex issues of treatment-resistant depression.

Conclusion: Treatment-resistant depression continues to challenge mental health care providers, and further relevant research involving newer drugs is warranted to improve the quality of life of patients with the disorder.

Keywords: antidepressants; biomarkers; somatic therapies; therapeutic options; treatment-resistant depression.

References

    1. Souery D, Amsterdam J, deMontigny C, et al. Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol. 1999;9:83–91.
    1. O’Reardon JP, Amsterdam JD. Treatment-resistant depression: progress and limitations. Psychiatr Ann. 1998;28:633–640.
    1. Nelson JC. Combined drug treatment strategies for major depression. Psych Ann. 1998;28:197–202.
    1. Ward MP, Irazoqui PP. Evolving refractory major depressive disorder diagnostic and treatment paradigms: toward closed-loop therapeutics. Front Neuroeng. 2010;3:7.
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington, DC: American Psychiatric Association; 2000. Practice Guideline for the Treatment of Patients with Major Depression; p. 2000. Text Revision.
    1. Cadieux RJ. Practical management of treatment-resistant depression. Am Fam Physician. 1998;58:2059–2062.
    1. Joffe RT, Levitt AJ, Sokolov ST. Augmentation strategies. J Clin Psychiatry. 1996;57:25–31.
    1. Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry. 2001;62:10–17.
    1. Thase ME, Rush JA. Treatment-resistant depression. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology. New York, NY: Raven; 1995.
    1. Keller MB. Issues in treatment-resistant depression. J Clin Psychiatry. 2005;66(Suppl 8):5–12.
    1. National Institute of Mental Health. Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Study. [Accessed March 12, 2012]. Available from: .
    1. Kennedy SH, Giacobbe P. Treatment resistant depression – advances in somatic therapies. Ann Clin Psychiatry. 2007;19:279–287.
    1. Huynh NN, McIntyre RS. What are the implications of the STAR*D trial for primary care? A review and synthesis. Prim Care Companion. J Clin Psychiatry. 2008;10:91–96.
    1. Cain RA. Navigating the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study: practical outcomes and implications for depression treatment in primary care. Prim Care. 2007;34:505–519.
    1. Sakolsky DJ, Perel JM, Emslie GJ, et al. Antidepressant exposure as a predictor of clinical outcomes in the Treatment of Resistant Depression in Adolescents (TORDIA) study. J Clin Psychopharmacol. 2011;31:92–97.
    1. Fava M, Katharine G, Davidson BA. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am. 1996;19:179–200.
    1. Thase ME, Rush AJ. When at first you don’t succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry. 1997;58(Suppl 13):23–29.
    1. Cowen PJ. Pharmacological management of treatment-resistant depression. Advances in Psychiatric Treatment. 1998;4:320–327.
    1. Treatment-resistant depression: no panacea, many uncertainties. Adverse effects are a major factor in treatment choice. Prescrire Int. 2011;20:128–133. [No authors listed]
    1. Ruhé HG, van Rooijen G, Spijker J, Peeters FP, Schene AH. Staging methods for treatment-resistant depression. A systematic review. J Affect Disord. 2012;137:35–45.
    1. Fekadu A, Wooderson SC, Rane LJ, Markopoulou K, Poon L, Cleare AJ. Long-term impact of residual symptoms in treatment-resistant depression. Can J Psychiatry. 2011;56:549–557.
    1. Asarnow JR, Porta G, Spirito A, et al. Suicide attempts and nonsuicidal self-injury in the treatment of resistant depression in adolescents: findings from the TORDIA study. J Am Acad Child Adolesc Psychiatry. 2011;50:772–781.
    1. Degenhardt EK, Jamal HH, Tormey S, Case M. Early weight gain as a predictor of substantial weight gain with olanzapine/fluoxetine combination: an analysis of 2 adult studies in treatment-resistant depression. J Clin Psychopharmacol. 2011;31:337–340.
    1. Bosmans JE, de Bruijne MC, de Boer MR, van Hout H, van Steenwijk P, van Tulder MW. Health care costs of depression in primary care patients in The Netherlands. Fam Pract. 2010;27:542–548.
    1. Simon GE, Revicki D, Heiligenstein J, et al. Recovery from depression, work productivity, and health care costs among primary care patients. Gen Hosp Psychiatry. 2000;22:153–162.
    1. Tierney JG., II Treatment-resistant depression: managed care considerations. J Manag Care Pharm. 2007;13(Suppl SA):S2–7.
    1. Parikh RM, Lebowitz BD. Current perspectives in the management of treatment-resistant depression. Dialogues Clin Neurosci. 2004;6:53–60.
    1. Greenberg P, Corey-Lisle PK, Birnbaum H, Marynchenko M, Claxton A. Economic implications of treatment-resistant depression among employees. Pharmacoeconomics. 2004;22:363–373.
    1. Lynch FL, Dickerson JF, Clarke G, et al. Incremental cost-effectiveness of combined therapy vs medication only for youth with selective serotonin reuptake inhibitor-resistant depression: treatment of SSRIresistant depression in adolescents trial findings. Arch Gen Psychiatry. 2011;68:253–262.
    1. Shelton RC, Osuntokun O, Heinloth AN, Corya SA. Therapeutic options for treatment-resistant depression. CNS Drugs. 2010;24:131–161.
    1. Rush AJ, Warden D, Wisniewski SR, et al. STAR*D: revising conventional wisdom. CNS Drugs. 2009;23:627–647.
    1. Thase ME. Treatment-resistant depression: prevalence, risk factors, and treatment strategies. J Clin Psychiatry. 2011;72:e18.
    1. Fava M, Rappe SM, Pava JA, Nierenberg AA, Alpert JE, Rosenbaum JF. Relapse in patients on long-term fluoxetine treatment. J Clin Psychiatry. 1995;56:52–55.
    1. Culpepper L. Why do you need to move beyond first-line therapy for major depression? J Clin Psychiatry. 2010;71(Suppl 1):4–9.
    1. Antai-Otong D. The art of prescribing. Monotherapy antidepressant: a thing of the past? Implications for the treatment of major depressive disorder. Perspect Psychiatr Care. 2007;43:142–145.
    1. Dunner DL, Rush AJ, Russell JM, Burke M, Woodard S, Wingard P, Allen J. Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression. J Clin Psychiatry. 2006;67:688–695.
    1. Phillips KA, Nierenberg AA. The assessment and treatment of refractory depression. J Clin Psychiatry. 1994;55:20–26.
    1. Vieta E, Colom F. Therapeutic options in treatment-resistant depression. Ann Med. 2011;43:512–530.
    1. Kostanjsek N. Use of The International Classification of Functioning, Disability and Health (ICF) as a conceptual framework and common language for disability statistics and health information systems. BMC Public Health. 2011;11(Suppl 4):53.
    1. Maalouf FT, Atwi M, Brent DA. Treatment-resistant depression in adolescents: review and updates on clinical management. Depress Anxiety. 2011;28:946–954.
    1. Shamseddeen W, Asarnow JR, Clarke G, et al. Impact of physical and sexual abuse on treatment response in the Treatment of Resistant Depression in Adolescent Study (TORDIA) J Am Acad Child Adolesc Psychiatry. 2011;50:293–301.
    1. Serretti A, Chiesa A, Calati R, et al. A preliminary investigation of the influence of CREB1 gene on treatment resistance in major depression. J Affect Disord. 2011;128:56–63.
    1. Zhang X, Beaulieu JM, Sotnikova TD, Gainetdinov RR, Caron MG. Tryptophan hydroxylase-2 controls brain serotonin synthesis. Science. 2004;305:1217.
    1. Zhang X, Gainetdinov RR, Beaulieu JM, et al. Loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. Neuron. 2005;45:11–16.
    1. Baud P. Risk factors and psychosocial disability of treatment resistant depression. Rev Med Suisse. 2011;7:1802–1806. French.
    1. Gotto J, Rapaport MH. Treatment options in treatment-resistant depression. Prim Psychiatry. 2005;12:42–50.
    1. Nemeroff CB. Augmentation strategies in patients with refractory depression. Depress Anxiety. 1996–1997;4:169–181.
    1. Joffe RT, Levitt AJ. Antidepressant failure: augmentation or substitution? J Psychiatry Neurosci. 1995;20:7–9.
    1. Orrell M, Collins E, Shergill S, Katona C. Management of depression in the elderly by general practitioners: I. Use of antidepressants. Fam Pract. 1995;12:5–11.
    1. Nierenberg AA, Papakostas GI, Petersen T, et al. Nortriptyline for treatment-resistant depression. J Clin Psychiatry. 2003;64:35–39.
    1. Thase ME, Blomgren SL, Barkett MA, et al. Fluoxetine treatment of patients with major depressive disorder who failed to initial treatment with sertraline. J Clin Psychiatry. 1997;58:16–21.
    1. Brown WA, Harrison W. Are patients who are intolerant to one SSRI intolerant to another? Psychopharmacol Bull. 1992;28:253–256.
    1. Zarate CA, Kando JC, Tohen M, Weiss MK, Cole JO. Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline? J Clin Psychiatry. 1996;57:67–71.
    1. Joffe RT, Levitt AJ, Sokolov ST, et al. Response to an open trial of a second SSRI in major depression. J Clin Psychiatry. 1996;57:114–115.
    1. Peselow ED, Philippi AM, Goodnick P, et al. The short- and long-term efficacy of paroxetine HC: B. data from a double blind cross-over study and from a year long term trial vs imipramine and placebo. Psychopharmacol Bull. 1989;25:272–276.
    1. Thase ME, Rush AJ, Cornstein SG, et al. Double blind switch of imipramine or sertraline treatment of antidepressant resistant chronic depression. Arch Gen Psychiatry. 2002;59:232–239.
    1. Nierenberg AA, Feighner JP, Rudolph R, et al. Venlafaxine for treatment resistant unipolar depression. J Clin Psychopharmacol. 1994;14:419–423.
    1. De Montigny C, Silverstone PH, Debonnel G, et al. Venlafaxine for treatment resistant depression. A Canadian, multicenter open label trial. J Clin Psychopharmacol. 1999;19:401–406.
    1. Kaplan EM. Efficacy of venlafaxine in patients with major depressive disorders who have unsustained or no response to selective serotonin reuptake inhibitors: an open-label, uncontrolled study. Clin Ther. 2002;24:1194–2000.
    1. Poirer ME, Boyer P. Venlafaxine and paroxetine in treatment resistant depression: double-blind randomized comparison. Br J Psychiatry. 1999;175:12–16.
    1. McGrath PJ, Fava M, Stewart JW, et al. Bupropion in SSRI-resistant depression. Presented at the 39th annual meeting of the American College of Neuropsychopharmacology; December 10–14, 2000; San Juan, Puerto Rico.
    1. Fava M, Dunner DL, Griest JH, et al. Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open label trial. J Clin Psychiatry. 2001;62:413–420.
    1. Thase ME, Kremer C, Rodridgues EH, et al. Mirtazapine versus sertraline in after SSRI nonresponse. Presented at the 39th annual meeting of the American College of Neuropsychopharmacology; December 10–14, 2000; San Juan, Puerto Rico.
    1. Rapaport MH, Gharabawi GM, Canuso CM, et al. Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology. 2006;31:2505–2513.
    1. Lenox-Smith AJ, Jiang Q. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor. Int Clin Psychopharmacol. 2008;23:113–119.
    1. Souery D, Serretti A, Calati R, et al. Citalopram versus desipramine in treatment resistant depression: effect of continuation or switching strategies: a randomized open study. World J Biol Psychiatry. 2011;12:364–375.
    1. Rosso G, Rigardetto S, Bogetto F, Maina G. A randomized, single-blind, comparison of duloxetine with bupropion in the treatment of SSRI-resistant major depression. J Affect Disord. 2012;136:172–176.
    1. Souery D, Serretti A, Calati R, et al. Switching antidepressant class does not improve response or remission in treatment-resistant depression. J Clin Psychopharmacol. 2011;31:512–516.
    1. Nelson JC. Managing treatment-resistant major depression. J Clin Psychiatry. 2003;64(Suppl 1):5–12.
    1. Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148:705–713.
    1. Fava M. Augmentation and combination strategies for complicated depression. J Clin Psychiatry. 2009;70:e40.
    1. Boyce P, Judd F. The place for the tricyclic antidepressants in the treatment of depression. Aust N Z J Psychiatry. 1999;33:323–327.
    1. Shelton RC. The use of antidepressants in novel combination therapies. J Clin Psychiatry. 2003;64:14–18.
    1. Thase ME, Mallinger AG, McKnight D, Himmelhoch JM. Treatment of imipramine-resistant recurrent depression, IV: a double-blind crossover study of tranylcypromine for anergic bipolar depression. Am J Psychiatry. 1992;149:195–198.
    1. Martín-López LM, Rojo JE, Gibert K, et al. The strategy of combining antidepressants in the treatment of major depression: clinical experience in Spanish outpatients. Depress Res Treat. 2011;2011:140194.
    1. Hannan N, Hamzah Z, Akinpeloye HO, Meagher D. Venlafaxine-mirtazapine combination in the treatment of persistent depressive illness. J Psychopharmacol. 2007;21:161–164.
    1. Malhi GS, Ng F, Berk M. Dual-dual action? Combining venlafaxine and mirtazapine in the treatment of depression. Aust N Z J Psychiatry. 2008;42:346–349.
    1. Triezenberg D, Vachon D, Helmen J, Schneider D. Clinical inquiries: how should you manage a depressed patient unresponsive to an SSRI? J Fam Pract. 2006;55:1081–1087.
    1. Nelson JC, Mazure CM, Bowers MB, Jr, Jatlow PI. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry. 1991;48:303–307.
    1. de Montigny C. Lithium addition in treatment-resistant depression. Int Clin Psychopharmacol. 1994;9:31–35.
    1. Philip NS, Carpenter LL, Tyrka AR, Price LH. Pharmacologic approaches to treatment resistant depression: a re-examination for the modern era. Expert Opin Pharmacother. 2010;11:709–722.
    1. Nemeroff CB. Use of atypical antipsychotics in refractory depression and anxiety. J Clin Psychiatry. 2005;66(Suppl 8):13–21.
    1. Philip NS, Carpenter LL, Tyrka AR, Price LH. Augmentation of antidepressants with atypical antipsychotics: a review of the current literature. J Psychiatr Pract. 2008;14:34–44.
    1. Sajatovic M, DiGiovanni S, Fuller M, et al. Nefazodone therapy in patients with treatment-resistant or treatment-intolerant depression and high psychiatric comorbidity. Clin Ther. 1999;21:733–740.
    1. Papakostas GI, Petersen TJ, Nierenberg AA, et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry. 2004;65:217–221.
    1. Parker G, Malhi G. Are atypical antipsychotic drugs also atypical antidepressants? Aust N Z J Psychiatry. 2001;35:631–638.
    1. Bobo WV, Shelton RC. Efficacy, safety and tolerability of Symbyax for acute-phase management of treatment-resistant depression. Expert Rev Neurother. 2010;10:651–670.
    1. Preskorn SH. Treatment options for the patient who does not respond well to initial antidepressant therapy. J Psychiatr Pract. 2009;5:202–210.
    1. Fabrazzo M, Perris F, Monteleone P, Esposito G, Catapano F, Maj M. Aripiprazole augmentation strategy in clomipramine-resistant depressive patients: an open preliminary study. Eur Neuropsychopharmacol. 2012;22:132–136.
    1. Boku S, Inoue T, Honma H, Matsubara S, Nakagawa S, Koyama T. Olanzapine augmentation of milnacipran for stage 2 treatment-resistant major depression: an open study. Hum Psychopharmacol. 2011 Jun 3; [Epub ahead of print.]
    1. Joffe RT, Singer W. A comparison of triiodothryonine and thyroxine in the potentiation of tricyclic antidepressants. Psychiatry Res. 1990;32:241–245.
    1. Bridges PK, Hodgkiss AD, Malizia AL. Practical management of treatment-resistant affective disorders. Br J Hosp Med. 1995;54:501–506.
    1. Joffe RT, Singer W, Levitt AJ, MacDonald C. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry. 1993;50:387–393.
    1. Artigas F, Romero L, Perez V, Alvarez E. Augmentation of antidepressant effects with 5HT-1A antagonists. Eur Neuropsychopharmacol. 1996;6(Suppl 3):16.
    1. Hansen RA, Dusetzina SB, Ellis AR, Stürmer T, Farley JF, Gaynes BN. Risk of adverse events in treatment-resistant depression: propensityscore-matched comparison of antidepressant augment and switch strategies. Gen Hosp Psychiatry. 2012;34:192–200.
    1. Fang Y, Yuan C, Xu Y, et al. OPERATION Study Team. A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese patients with treatment-resistant major depression. J Clin Psychopharmacol. 2011;31:638–642.
    1. Barbee JG, Thompson TR, Jamhour NJ, et al. A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression. J Clin Psychiatry. 2011;72:1405–1412.
    1. Mowla A, Kardeh E. Topiramate augmentation in patients with resistant major depressive disorder: a double-blind placebocontrolled clinical trial. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:970–973.
    1. Anderson IM, Sarsfield A, Haddad PM. Efficacy, safety and tolerability of quetiapine augmentation in treatment resistant depression: an open-label, pilot study. J Affect Disord. 2009;117:116–119.
    1. Thase ME, Friedman ES, Biggs MM, et al. Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry. 2007;164:739–752.
    1. Sharma V, Mazmanian D, Persad E, Kueneman K. A comparison of comorbid patterns in treatment-resistant unipolar and bipolar depression. Can J Psychiatry. 1995;40:270–274.
    1. Gruber AJ, Hudson JI, Pope HG., Jr The management of treatment-resistant depression in disorders on the interface of psychiatry and medicine. Fibromyalgia, chronic fatigue syndrome, migraine, irritable bowel syndrome, atypical facial pain, and premenstrual dysphoric disorder. Psychiatr Clin North Am. 1996;19:351–369.
    1. Jann MW, Slade JH. Antidepressant agents for the treatment of chronic pain and depression. Pharmacotherapy. 2007;27:1571–1587.
    1. Franco-Bronson K. The management of treatment-resistant depression in the medically ill. Psychiatr Clin North Am. 1996;19:329–350.
    1. Fink M. Convulsive therapy: a review of the first 55 years. J Affect Disord. 2001;63:1–15.
    1. Khalid N, Atkins M, Tredget J, Giles M, Champney-Smith K, Kirov G. The effectiveness of electroconvulsive therapy in treatment-resistant depression: a naturalistic study. J ECT. 2008;24:141–145.
    1. Sackheim HA, Prudic J, Devanand DP, Decina P, Kerr B, Malitz S. The impact of medication resistance and continuation pharmacotherapy on relapse following response to electroconvulsive therapy in major depression. J Clin Psychopharmacol. 1990;10:96–104.
    1. Perugi G, Medda P, Zanello S, Toni C, Cassano GB. Episode length and mixed features as predictors of ECT nonresponse in patients with medication-resistant major depression. Brain Stimul. 2012;5:18–24.
    1. Ghaziuddin N, Dumas S, Hodges E. Use of continuation or maintenance electroconvulsive therapy in adolescents with severe treatment-resistant depression. J ECT. 2011;27:168–174.
    1. Torres CV, Lozano AM. Deep brain stimulation in the treatment of therapy-refractory depression. Rev Neurol. 2008;47:477–482.
    1. Kennedy SH, Giacobbe P. Treatment resistant depression – advances in somatic therapies. Ann Clin Psychiatry. 2007;19:279–287.
    1. Hoy KE, Fitzgerald PB. Magnetic seizure therapy for treatment-resistant depression. Expert Rev Med Devices. 2011;8:723–732.
    1. Jhanwar VG, Bishnoi RJ, Jhanwar MR. Utility of repetitive transcranial stimulation as an augmenting treatment method in treatment-resistant depression. Indian J Psychol Med. 2011;33:92–96.
    1. Blumberger DM, Mulsant BH, Fitzgerald PB, et al. A randomized double-blind sham-controlled comparison of unilateral and bilateral repetitive transcranial magnetic stimulation for treatment-resistant major depression. World J Biol Psychiatry. 2011 Jul 8; [Epub ahead of print.]
    1. Dell’osso B, Camuri G, Castellano F, et al. Meta-review of metanalytic studies with repetitive transcranial magnetic stimulation (rTMS) for the treatment of major depression. Clin Pract Epidemiol Ment Health. 2011;7:167–177.
    1. Palm U, Schiller C, Fintescu Z, et al. Transcranial direct current stimulation in treatment resistant depression: a randomized double-blind, placebo-controlled study. Brain Stimul. 2011 Sep 7; [Epub ahead of print.]
    1. Warnell RL, Elahi N. Introduction of vagus nerve stimulation into a maintenance electroconvulsive therapy regimen: a case study and cost analysis. J ECT. 2007;23:114–119.
    1. Sackeim HA, Rush AJ, George MS, et al. Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome. Neuropsychopharmacology. 2001;25:713–728.
    1. Lozano AM, Giacobbe P, Hamani C, et al. A multicenter pilot study of subcallosal cingulate area deep brain stimulation for treatment-resistant depression. J Neurosurg. 2012;116:315–322.
    1. Kennedy SH, Giacobbe P, Rizvi SJ, et al. Deep brain stimulation for treatment-resistant depression: follow-up after 3 to 6 years. Am J Psychiatry. 2011;168:502–510.
    1. Puri BK, Counsell SJ, Hamilton G, Richardson AJ, Horrobin DF. Eicosapentaenoic acid in treatment-resistant depression associated with symptom remission, structural brain changes and reduced neuronal phospholipid turnover. Int J Clin Pract. 2001;55:560–563.
    1. Podawiltz A, Culpepper L. Treatment-resistant depression in Hispanic patients. J Clin Psychiatry. 2010;71(6):e12.
    1. Nemeroff CB. Improving antidepressant adherence. J Clin Psychiatry. 2003;64(Suppl 18):25–30.
    1. Mota-Pereira J, Carvalho S, Silverio J, et al. Moderate physical exercise and quality of life in patients with treatment-resistant major depressive disorder. J Psychiatr Res. 2011;45:1657–1659.
    1. Brent D, Emslie J, Clark G, et al. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA. 2008;299:901–913.
    1. Hetrick SE, Cox GR, Merry SN. Treatment-resistant depression in adolescents: is the addition of cognitive behavioral therapy of benefit? Psychol Res Behav Manag. 2011;4:97–112.
    1. Shamseddeen W, Clarke G, Wagner KD, et al. Treatment-resistant depressed youth show a higher response rate if treatment ends during summer school break. J Am Acad Child Adolesc Psychiatry. 2011;50:1140–1148.
    1. Trivedi RB, Nieuwsma JA, Williams JW., Jr Examination of the utility of psychotherapy for patients with treatment resistant depression: a systematic review. J Gen Intern Med. 2011;26:643–650.
    1. Vitiello B, Emslie G, Clarke G, et al. Long-term outcome of adolescent depression initially resistant to selective serotonin reuptake inhibitor treatment: a follow-up study of the TORDIA sample. J Clin Psychiatry. 2011;72:388–396.
    1. Sanacora G, Zarate CA, Krystal JH, Manji HK. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov. 2008;7:426–437.
    1. Murrough JW, Charney DS. Lifting the mood with ketamine. Nat Med. 2010;16:1384–1385.
    1. Ibrahim L, Diazgranados N, Luckenbaugh DA, et al. Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:1155–1159.
    1. Witkin JM, Li X. New approaches to the pharmacological management of major depressive disorder. Adv Pharmacol. 2009;57:347–379.
    1. Liang Y, Richelson E. Triple reuptake inhibitors: next-generation antidepressants. Prim Psychiatry. 2008;15:50–56.
    1. Marks DM, Pae C, Patkar AA. Triple reuptake inhibitors: a premise and a promise. Psychiatry Investig. 2008;5:142–147.
    1. Trivedi MH. Treatment-resistant depression: new therapies on the horizon. Ann Clin Psychiatry. 2003;15:59–70.
    1. Loftis JM. Sertoli cell therapy: a novel possible treatment strategy for treatment-resistant major depressive disorder. Med Hypotheses. 2011;77:35–42.
    1. Furey ML, Drevets WC. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry. 2006;63:1121–1129.
    1. George TP, Sacco KA, Vessicchio JC, Weinberger AH, Shytle RD. Nicotinic antagonist augmentation of selective serotonin reuptake inhibitor-refractory major depressive disorder: a preliminary study. J Clin Psychopharmacol. 2008;28:340–344.
    1. Birkenhäger TK, van den Broek WW, Moleman P, Bruijn JA. Outcome of a 4-step treatment algorithm for depressed inpatients. J Clin Psychiatry. 2006;67:1266–1271.
    1. Connolly KR, Thase ME. If at first you don’t succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs. 2011;71:43–64.
    1. Wan DD, Kundhur D, Solomons K, Yatham LN, Lam RW. Mirtazapine for treatment-resistant depression: a preliminary report. J Psychiatry Neurosci. 2003;28:55–59.
    1. Stotz G, Woggon B, Angst J. Psychostimulants in the therapy of treatment-resistant depression. Review of the literature and findings from a retrospective study in 65 depressed patients. Dialogues Clin Neurosci. 1999;1:165–174.
    1. Eisendrath S, Chartier M, McLane M. Adapting mindfulness-based cognitive therapy for treatment-resistant depression: a clinical case study. Cogn Behav Pract. 2011;18:362–370.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner